EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with ...

EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with ...

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this month at Frankston Hospital, VictoriaFurther site to follow at Curie Oncology, Singapore

EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North Sydney Recruitment to open this month at Frankston Hospital, Victoria Further site to follow at Curie Oncology, Singapore SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) — EnGeneIC Pty Ltd, a Sydney-based biotechnology company and leader in innovative cancer therapies, has announced the successful dosing of the first patient in its open-label, multicentre, Phase I/I…